1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: Outcomes by metabolic tumor volume
    Journal Article

    Locke, F. L.; Oluwole, O. O.; Kuruvilla, J.; Thieblemont, C.; Morschhauser, F.; Salles, G.; Rowe, S. P.; Vardhanabhuti, S.; Winters, J.; Filosto, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
    Journal Article

    Silbermann, R.; Laubach, J.; Kaufman, J. L.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
    Journal Article

    Zeidan, A. M.; Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E.; de Menezes, D. L.; Rose, S.; Boss, I.; Halene, S.; Haferlach, T.; more...
    Therapeutic Advances in Hematology (2024)

    Fulltext@MSK | Save
  • Phase 3 CLEAR study in patients with advanced renal cell carcinoma: Outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Journal Article

    Grünwald, V.; Powles, T.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C.; Motzer, R.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Onkourologiya (2024)

    Fulltext@MSK | Save
  • The relationship between health-related quality of life and overall survival in patients with advanced renal cell carcinoma in CheckMate 214
    Journal Article

    Cella, D.; Choueiri, T. K.; Hamilton, M.; Blum, S. I.; Ivanescu, C.; Karu, K.; Ejzykowicz, F.; Motzer, R. J.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Neoadjuvant treatment of mismatch repair–deficient colon cancer — Clinically meaningful?
    Editorial

    Cercek, A.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study
    Journal Article

    Xie, M.; Vuko, M.; Rodriguez-Canales, J.; Zimmermann, J.; Schick, M.; O’Brien, C.; Paz-Ares, L.; Goldman, J. W.; Garassino, M. C.; Gay, C. M.; more...
    Molecular Cancer (2024)

    Fulltext@MSK | Save
  • Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): A randomised, open-label, phase 3 trial from the Children's Oncology Group
    Journal Article

    Gupta, A. A.; Xue, W.; Harrison, D. J.; Hawkins, D. S.; Dasgupta, R.; Wolden, S.; Shulkin, B.; Qumseya, A.; Routh, J. C.; MacDonald, T.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Gelderblom, H.; Bhadri, V.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; López Pousa, A.; Abdul Razak, A.; Italiano, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer
    Journal Article

    Patell, R.; Hsu, C.; Shi, M.; Grosso, M. A.; Duggal, A.; Büller, H. R.; Raskob, G.; Zwicker, J. I.
    Haematologica (2024)

    Fulltext@MSK | Save